- Trials with a EudraCT protocol (288)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
288 result(s) found for: SARS coronavirus.
Displaying page 9 of 15.
EudraCT Number: 2020-002233-15 | Sponsor Protocol Number: NICCAM-001 | Start Date*: 2020-06-17 | |||||||||||
Sponsor Name:Charité Research Organisation GmbH | |||||||||||||
Full Title: A randomized, single blind, placebo-controlled, multiple dose, parallel-arm study to investigate the safety and preliminary efficacy of the combination of Niclosamide and Camostat to treat COVID-19... | |||||||||||||
Medical condition: SARS-Coronavirus 2 disease 2019 (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005576-35 | Sponsor Protocol Number: CP-PRO-CoVLP-021 | Start Date*: 2021-05-06 | |||||||||||
Sponsor Name:Medicago R&D Inc. | |||||||||||||
Full Title: A Randomized, Observer-Blind, Placebo-Controlled, Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years o... | |||||||||||||
Medical condition: Covid-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005759-18 | Sponsor Protocol Number: CV43043 | Start Date*: 2021-05-10 | |||||||||||
Sponsor Name:F. Hoffmann La Roche Ltd. | |||||||||||||
Full Title: A MULTICENTER, PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OUTPATIENT STUDY TO EVALUATE THE EFFICACY, SAFETY, AND ANTIVIRAL ACTIVITY OF RO7496998 AT-527 IN PATIENTS WITH MILD OR MODERAT... | |||||||||||||
Medical condition: Mild to Moderate coronavirus disease 2019 (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) DK (Prematurely Ended) FR (Prematurely Ended) PT (Prematurely Ended) IT (Prematurely Ended) RO (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001040-10 | Sponsor Protocol Number: CoVVac | Start Date*: 2021-04-26 | |||||||||||
Sponsor Name:Medical University of Graz | |||||||||||||
Full Title: Humoral and cellular immune response to COVID-19 vaccines in immunocompromised and healthy individuals – The CoVVac study | |||||||||||||
Medical condition: Active immunisation to prevent COVID-19 in immunocompromised individuals. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001811-94 | Sponsor Protocol Number: M18-868 | Start Date*: 2022-01-28 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Adva... | |||||||||||||
Medical condition: C-Met overexpressing EGFR wildtype, non-squamous non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Trial now transitioned) CZ (Trial now transitioned) SE (Trial now transitioned) BE (Trial now transitioned) HU (Completed) FR (Trial now transitioned) RO (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000455-39 | Sponsor Protocol Number: C21-109-09 | Start Date*: 2021-04-09 | |||||||||||
Sponsor Name:Pharma Holdings AS | |||||||||||||
Full Title: A double-blind, placebo-controlled, interventional parallel group study to evaluate the antiviral effect of a single nasal application of LTX-109 3% gel, in comparison to placebo gel, in subjects w... | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000166-15 | Sponsor Protocol Number: IVM-2021-01 | Start Date*: 2021-03-03 |
Sponsor Name:Meditop Gyógyszeripari Kft | ||
Full Title: A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ivermectin in asymptomatic and mild severity COVID-19 patients | ||
Medical condition: COVID 19 infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2021-003191-14 | Sponsor Protocol Number: 21CH135 | Start Date*: 2021-08-16 | |||||||||||
Sponsor Name:CHU SAINT-ETIENNE | |||||||||||||
Full Title: Cohort assessing the immunogenicity and the safety of the COVID-19 Vaccine Janssen in healthy volunteers based on 3 age groups: 65 years or older - 55 to 65 years - 18 to 45 years - Covicompare-Jan... | |||||||||||||
Medical condition: volunteers | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001162-12 | Sponsor Protocol Number: EFC16844 | Start Date*: 2020-03-26 | |||||||||||
Sponsor Name:Sanofi-aventis Recherche et Développement | |||||||||||||
Full Title: An adaptive phase 3, randomized, double-blind, placebo-controlled, study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19 | |||||||||||||
Medical condition: Corona virus infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001805-21 | Sponsor Protocol Number: RA486120 | Start Date*: 2020-05-15 |
Sponsor Name:University Hospital Coventry & Warwickshire | ||
Full Title: Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination with Oseltamivir, in Adults with Coronavirus Disease COVID-19 | ||
Medical condition: Sars-Cov-2 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003643-29 | Sponsor Protocol Number: VAC31518COV3009 | Start Date*: 2020-11-10 | |||||||||||
Sponsor Name:Janssen Vaccines & Prevention B.V. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older E... | |||||||||||||
Medical condition: Healthy Volunteers, with or without comorbidities (Prevention of SARS-CoV-2-mediated COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) ES (Temporarily Halted) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001675-33 | Sponsor Protocol Number: VPM1002-DE-3.07CoV | Start Date*: 2020-05-29 | |||||||||||
Sponsor Name:Vakzine Projekt Management GmbH | |||||||||||||
Full Title: A phase III, randomized, double-blind, placebo-controlled, multicentre, clinical trial to assess the efficacy and safety of VPM1002 in reducing hospital admissions and/or severe respiratory infecti... | |||||||||||||
Medical condition: infectious respiratory diseases (e.g. COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001735-10 | Sponsor Protocol Number: 21816 | Start Date*: 2021-05-28 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: COVID-19: A Phase 3, open-label, parallel group, multicenter clinical study to evaluate the safety, reactogenicity, and immunogenicity of the investigational SARS-CoV-2 mRNA vaccine CVnCoV in parti... | |||||||||||||
Medical condition: Vaccination for prophylaxis of coronavirus disease 2019 (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001331-26 | Sponsor Protocol Number: PROLIFIC2020 | Start Date*: 2020-04-14 | |||||||||||
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust | |||||||||||||
Full Title: ChemoPROphyLaxIs For covId-19 infeCtious disease (the PROLIFIC trial) | |||||||||||||
Medical condition: Coronavirus disease 2019 (COVID-19) caused by the infection, SARS-CoV-2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001928-34 | Sponsor Protocol Number: HALT_Covid-19 | Start Date*: 2020-05-28 |
Sponsor Name:Capio S:t Görans Sjukhus | ||
Full Title: Inhalation of Ciclesonide for patients with Covid-19: A randomised open treatment study (HALT Covid-19). | ||
Medical condition: Covid-19 pneumonia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000413-17 | Sponsor Protocol Number: COVERS | Start Date*: 2021-02-24 |
Sponsor Name:Region Skåne - Kliniska Studier Sverige, Forum Söder | ||
Full Title: COVERS (COVID-Vaccination Efficiency Risk and Safety Study) - an open trial for follow-up of efficacy, risk and safety in persons who have been vaccinated against SARS-CoV-2 in Region Skåne with va... | ||
Medical condition: Coronavirus disease 2019 (COVID-19) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001329-30 | Sponsor Protocol Number: 2020P000787 | Start Date*: 2020-04-09 |
Sponsor Name:Massachussetts General Hospital | ||
Full Title: Inhaled Nitric Oxide Gas Therapy in Mechanically Ventilated Patients with Severe Acute Respiratory Syndrome in COVID-19 | ||
Medical condition: ARDS caused by COVID-19 infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003401-60 | Sponsor Protocol Number: CT-P59_3.1 | Start Date*: 2020-09-30 | |||||||||||
Sponsor Name:CELLTRION, Inc. | |||||||||||||
Full Title: A Phase 2/3, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination with Standard of Care in Hospitalized Patients with SARS... | |||||||||||||
Medical condition: Novel severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: RO (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002211-21 | Sponsor Protocol Number: SGS.1656.201 | Start Date*: 2020-07-31 | |||||||||||
Sponsor Name:St George Street Capital Ltd | |||||||||||||
Full Title: A Phase II, randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in diabetic patients hospitalised with suspected or confirmed COVID-19. The ARCA... | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000982-18 | Sponsor Protocol Number: NOR-SOLIDARITY | Start Date*: 2020-03-26 | |||||||||||
Sponsor Name:Oslo University Hospital | |||||||||||||
Full Title: The NOR Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19). | |||||||||||||
Medical condition: SARS-COV-2 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) SE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
